T~Y Lim / Shutterstock

16 May 2024FeaturesEuropeMarisa Woutersen

Moderna’s COVID-19 pledge dilemma

As the company challenges Pfizer and BioNTech over COVID-19 vaccine patents, issues over the enforceability of pledges made during the pandemic may make pharma think twice in future, finds Marisa Woutersen.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Sandoz wins $137.2m payout for lost profits in generic launch

Dexcom suffers second patent revocation at hands of UPC

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

Novo Nordisk files fresh lawsuits to intercept Wegovy generics

UPC delivers first 'imminent infringement' decision in biosimilar dispute

AstraZeneca unit draws line under Samsung dispute